Elevai Labs Inc. announced the establishment of two new wholly owned subsidiaries, Elevai Biosciences Inc., and Elevai Skincare Inc. These ventures mark a strategic shift towards the development of next-generation aesthetic medicines and efforts to improve the economics of its commercialized exosome skincare brand. In conjunction with the reorganization of its skincare operations, Elevai Skincare?s Chris Kraneiss, Chief Commercial Officer (CCO) of Elevai, and Brenda Buechler, Chief Marketing Officer, will transition from their roles from Elevai Labs Inc. to oversee operations within Elevai Skincare. This strategic realignment aims to drive operational efficiency and accelerate revenue growth within the skincare segment.